Beyond the Numbness: Nonpharmacological Strategies for Managing Chemotherapy-Induced Peripheral Neuropathy

Rethinking Bedside CIPN Management Beyond Standard Toxicity Scores

Chemotherapy-induced peripheral neuropathy, or CIPN, is one of the most persistent treatment-related complications encountered in oncology practice. Depending on the regimen, dose, cancer type, and assessment method, neuropathy affects approximately 19 to 85 percent of patients. Taxanes, platinum compounds, vinca alkaloids, and several newer agents may produce numbness, tingling, burning pain, loss of dexterity, weakness, or impaired balance. Symptoms can continue well after chemotherapy ends, limiting work, self-care, driving, walking, and other activities that define independence. A recent review of acupuncture research describes CIPN as both a sensory and functional disorder, not simply an unpleasant symptom to record at the end of a treatment cycle. Current CIPN evidence supports earlier recognition and a broader approach to prevention and rehabilitation.

In many infusion settings, however, clinical decisions remain anchored to subjective Common Terminology Criteria for Adverse Events, or CTCAE, grades. CTCAE grading is valuable for communication, research, and treatment safety, but ordinal scores may not identify the first measurable decline in sensation, hand function, or postural control. A patient may describe symptoms as “mild” while quietly avoiding buttons, dropping utensils, or holding onto furniture. By the time neuropathy reaches a clearly documented grade 2 or grade 3, the opportunity to protect nerve function and preserve chemotherapy dose intensity may already have narrowed. For patients researching supportive strategies alongside their clinical care, reliable education such as evidence-based cancer care resources can reinforce the importance of reporting subtle changes promptly.

Proactive nursing practice requires a shift from waiting for severe symptoms to emerge toward identifying functional change at every relevant treatment contact. The objective is not to replace CTCAE grading, but to complement it with brief, repeatable measures and a clear escalation pathway. Core nonpharmacological strategies include regional cryotherapy during selected infusions, sensorimotor and balance training, and appropriately supervised acupuncture. Together, these interventions can support patient safety, manual dexterity, mobility, and treatment continuity while pharmacological options are considered or optimized.

• Screen for sensory, motor, autonomic, pain, and balance changes before each neurotoxic treatment cycle.
• Document function in concrete terms, such as buttoning clothing, opening containers, writing, walking, or climbing stairs.
• Pair early assessment with prevention, rehabilitation, education, and timely communication with the prescribing oncology team.

Clinical Blind Spots of Reactive Grading Systems

CTCAE scores rely heavily on patient descriptions and the clinician”s interpretation of how symptoms affect activities of daily living. That approach can miss early deficits for several reasons. Patients may normalize numbness because they expect chemotherapy to cause side effects, may hesitate to report symptoms for fear of treatment reduction, or may describe a symptom without recognizing its functional significance. Conversely, two patients with the same grade may have very different risks. Mild tingling in the fingertips may be inconvenient for one person but clinically consequential for a surgeon, musician, driver, or patient who must manage insulin or medications independently.

Evidence also indicates that oncology teams do not always have consistent training or workflows for neurological assessment. In a survey of 148 oncology nurses in Jordan, the mean knowledge score was 8.98 out of 16, only 58.8 percent considered CIPN assessment necessary in oncology practice, and neurological physical assessment was generally absent from routine care. A more recent study of 96 oncology nurses in Turkey found that 76 percent had received no peripheral neuropathy training, while only 35.4 percent assessed patients receiving neurotoxic chemotherapy at every visit or cycle. These findings, reported in the oncology nursing practice study and the recent nurse knowledge study, highlight a systems problem rather than an individual failure.

Delayed recognition can lead to avoidable dose delays, dose reductions, treatment changes, and persistent loss of function. A practical solution is to combine the CTCAE grade with validated functional assessments and a consistent patient interview. Functional assessments bridge the clinical gap highlighted in oncology nursing practice studies regarding sensory tracking, particularly when they are built into the infusion pre-check rather than added as an optional task.

• Ask what the patient can no longer do, not only whether numbness or pain is present.
• Compare findings with the patient”s baseline and the previous treatment cycle.
• Escalate new functional decline before symptoms become severe enough to interfere with essential activities.

Implementing Rapid Functional Neuro-Assessments at the Infusion Chair

A focused assessment can be completed in under three minutes when it is standardized. Begin with a brief patient-reported screen: new or worsening numbness, tingling, burning pain, temperature sensitivity, weakness, dizziness, constipation, urinary changes, or difficulty walking. Ask one function-focused question, such as, “Have you had trouble fastening buttons, opening packages, using your phone, writing, or walking safely since the last treatment?” This wording often reveals a meaningful change more effectively than a general question about side effects.

Next, observe gait and transfers as the patient moves to the infusion chair. If clinically appropriate, assess heel-to-toe stability or a short balance task, while maintaining fall precautions. A simple monofilament screen can compare light-touch perception at consistent sites on the fingers and feet. A timed button test or coin-handling task provides a quick view of fine-motor control. Grip strength, when equipment is available, should be compared with the patient”s prior result rather than interpreted as an isolated number. Any new asymmetry, rapidly progressive weakness, or significant gait instability warrants prompt clinical review.

Documentation should make the trend visible. Record the symptom pattern, affected extremities, functional examples, objective findings, and the patient”s safety needs. A note stating “neuropathy unchanged” is less useful than “increased fingertip numbness, now drops coins and needs assistance fastening shirt; monofilament sensation reduced at bilateral index fingers; gait steady.” Standardized flowsheets or electronic prompts can trigger an early discussion with the oncologist, pharmacist, advanced practice nurse, or clinical nurse specialist before grade 3 deficits develop. The broader review of acupuncture and CIPN also reinforces that symptoms may involve pain, sensory function, and quality of life, making multidimensional follow-up essential.

Targeted Cryotherapy and Hypothermic Protocols During Infusion

Cryotherapy aims to reduce exposure of distal nerves to circulating neurotoxic chemotherapy. Cooling the hands and feet produces local vasoconstriction, which may decrease blood flow and limit the amount of taxane reaching peripheral nerve endings during infusion. Cold may also reduce cellular metabolism and inflammatory signaling, although the precise protective mechanism remains under investigation. The strategy is most commonly studied with paclitaxel and related taxane regimens, and it should be considered regimen-specific rather than automatically applied to every neurotoxic drug.

Evidence is promising but not definitive. A systematic review of four randomized trials involving 215 patients found that frozen gloves, stockings, or crushed ice generally reduced paclitaxel-induced neuropathy across measures such as FACT-NTX and patient neuropathy questionnaires, although results were inconsistent and samples were small. The systematic review emphasized differences in cooling devices, timing, outcome measures, and study quality. A prospective propensity score-matched breast cancer study found that cooling from 15 minutes before chemotherapy through 15 minutes afterward, with cryostats replaced every 45 minutes, was associated with less cold sensitivity, hand and foot numbness, and hand tingling. Physical function and quality of life also improved in the cryotherapy group, but the authors recommended further research to establish optimal timing and duration. The propensity-matched study should therefore inform practice without being treated as conclusive proof for every regimen.

Safe implementation requires a written protocol, patient selection criteria, and active skin surveillance. Confirm that the patient has no significant cold intolerance, severe peripheral vascular disease, impaired skin integrity, or another contraindication identified by local policy. Explain that the gloves or slippers will feel very cold and that pain, excessive blanching, burning, numbness beyond the expected cooling sensation, or skin color change must be reported immediately. Avoid direct ice contact with unprotected skin, ensure appropriate fit, and inspect hands and feet before, during, and after treatment.

1. Verify the chemotherapy agent, treatment plan, eligibility criteria, and institutional cryotherapy procedure.
2. Apply appropriately sized frozen gloves or slippers approximately 15 minutes before infusion when supported by the protocol.
3. Maintain cooling throughout administration, replacing devices at the scheduled interval, commonly about every 45 minutes.
4. Assess skin color, temperature, sensation, discomfort, and pressure points at regular intervals.
5. Continue cooling after chemotherapy for the protocol-defined period, often approximately 15 minutes, then rewarm gradually and document tolerance.

Sensorimotor Rehabilitation and Restorative Acupuncture

Sensorimotor rehabilitation addresses the functional consequences of neuropathy directly. Reduced sensation in the feet can impair proprioception, the body”s awareness of position, while weakness and altered gait increase fall risk. A physical therapist can develop a graded program that includes ankle and toe movement, lower-extremity strengthening, sit-to-stand practice, controlled weight shifting, tandem stance, and safe balance exercises. Resistance training should be individualized around fatigue, bone health, treatment-related weakness, and any orthopedic or cardiopulmonary limitations.

Patients should receive clear safety instructions rather than a generic recommendation to exercise. Balance activities should begin near a stable support surface, with footwear that fits securely and adequate lighting. Nurses can reinforce daily foot inspection, removal of tripping hazards, use of handrails, and prompt reporting of falls or near falls. In the infusion setting, a brief review of walking confidence and recent stumbles may identify a referral need even when the patient denies pain. The goal is not athletic performance; it is preservation of safe transfers, community mobility, self-care, and confidence.

Acupuncture is another potential adjunct, particularly for patients with persistent symptoms despite education and standard medical management. The 2024 narrative review synthesized 19 randomized controlled trials involving 1,174 participants and found associations with improved neuropathic pain, sensory function, and quality of life. Proposed mechanisms include endogenous opioid release, neurotransmitter modulation, neuroplasticity, altered pain-pathway signaling, autonomic regulation, and improved microcirculation. Protocols varied, but many involved two or three sessions weekly for four to twelve weeks, with commonly used points including ST36, LI4, and SP6. Evidence appears most developed for taxane- and platinum-related CIPN, yet heterogeneity and limited trial quality mean acupuncture should be presented as a promising adjunct, not a guaranteed treatment.

• Infusion nurses identify symptom trends, provide education, initiate safety screening, and communicate changes before treatment.
• Licensed acupuncturists assess suitability, use infection-control precautions, individualize treatment, and monitor adverse effects such as bruising or dizziness.
• Physical therapists evaluate gait, strength, balance, assistive-device needs, and progression of a home exercise program.
• Oncology prescribers and pharmacists review regimen risk, dose intensity, concurrent medications, and escalation options.

Interdisciplinary coordination works best when referrals are triggered by defined findings, such as new balance impairment, repeated dropping of objects, progressive sensory loss, or symptoms that interfere with work or self-care. Patient goals should guide the plan. Preserving the ability to walk independently may matter more to one patient, while maintaining hand dexterity for employment or caregiving may be the primary priority for another.

Building a Proactive Bedside Framework for Nerve Preservation

Effective CIPN management begins before severe toxicity appears. Functional screening makes early change visible, cryotherapy may reduce distal exposure during selected infusions, and rehabilitation or acupuncture can address the sensory, motor, pain, and quality-of-life dimensions of established neuropathy. None of these strategies eliminates the need for CTCAE grading, medication review, or oncologist-led treatment decisions. Their value lies in adding earlier, patient-centered information to the decision-making process.

Every infusion unit can begin with three operational shifts that require more consistency than new technology:

• Make functional screening routine. Add a brief symptom and activity check, an observation of gait or transfers, and a simple objective measure to the pre-infusion workflow for patients receiving neurotoxic therapy.
• Use a visible escalation pathway. Define which findings require same-day prescriber notification, physical therapy referral, acupuncture consultation, fall-risk education, or treatment review.
• Track trends across cycles. Use standardized documentation so that small changes in sensation, dexterity, balance, and daily function are recognized before they become permanent barriers.

Oncology nurses are uniquely positioned to protect long-term survivorship because they see patients repeatedly, often before a formal specialist assessment occurs. By listening for functional change, examining beyond the toxicity score, teaching practical safety measures, and coordinating timely interventions, the infusion team becomes an active defender of nerve function and independence. Proactive bedside care cannot guarantee that CIPN will be prevented, but it can make injury more visible, response more timely, and chemotherapy delivery safer for the person receiving it.